Page last updated: 2024-09-05

roxifiban and Thrombocytopenia

roxifiban has been researched along with Thrombocytopenia in 3 studies

*Thrombocytopenia: A subnormal level of BLOOD PLATELETS. [MeSH]

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrett, YC; Billheimer, JT; Cromley, DA; Daly, RN; Ebling, W; He, B; Hollis, GF; Hua, TA; Kieras, CJ; Pedicord, DL; Pieniaszek, HJ; Rossi, RJ; Seiffert, D; Sferruzza, A; Stein, RB; Stern, AM; Wynn, R	1
Billheimer, JT; Breth, L; Dicker, I; Hollis, GF; O'Neil, K; Pedicord, DL; Seiffert, D; Stern, AM; Wynn, R	1
Billheimer, JT; Bradley, JD; Cromley, DA; Daly, RN; Dicker, IB; Godonis, HE; Gorko, MA; Grimminger, LC; He, B; Hollis, GF; Kieras, CJ; Pedicord, DL; Seiffert, D; Spitz, SM; Stern, AM; Thomas, BE; Wynn, R; Zolotarjova, NI	1

Trials

1 trial(s) available for roxifiban and Thrombocytopenia

Article	Year
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood, 2003, Jan-01, Volume: 101, Issue:1 Topics: Amidines; Autoantibodies; Blood Platelets; Humans; Incidence; Isoxazoles; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Thrombocytopenia; Time Factors; Vascular Diseases	2003

Article

Year

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

Blood, 2003, Jan-01, Volume: 101, Issue:1

Topics: Amidines; Autoantibodies; Blood Platelets; Humans; Incidence; Isoxazoles; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Thrombocytopenia; Time Factors; Vascular Diseases

2003

Other Studies

2 other study(ies) available for roxifiban and Thrombocytopenia

Article	Year
CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists. Thrombosis and haemostasis, 2003, Volume: 89, Issue:3 Topics: Amidines; Animals; Antibodies, Monoclonal; Blood Platelets; Cysteine Endopeptidases; Humans; In Vitro Techniques; Isoxazoles; Mice; Neoplasm Proteins; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, IgG; Thrombocytopenia	2003
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Administration, Oral; Amidines; Animals; Antibodies; Biological Availability; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Epitopes; Humans; Isoxazoles; Kinetics; Pan troglodytes; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Sensitivity and Specificity; Thrombocytopenia	2002

Article

Year

CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists.

Thrombosis and haemostasis, 2003, Volume: 89, Issue:3

Topics: Amidines; Animals; Antibodies, Monoclonal; Blood Platelets; Cysteine Endopeptidases; Humans; In Vitro Techniques; Isoxazoles; Mice; Neoplasm Proteins; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, IgG; Thrombocytopenia

2003

Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.

Blood, 2002, May-15, Volume: 99, Issue:10

Topics: Administration, Oral; Amidines; Animals; Antibodies; Biological Availability; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Epitopes; Humans; Isoxazoles; Kinetics; Pan troglodytes; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Sensitivity and Specificity; Thrombocytopenia

2002